GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Avant Diagnostics Inc (GREY:AVDX) » Definitions » Cyclically Adjusted PS Ratio

Avant Diagnostics (Avant Diagnostics) Cyclically Adjusted PS Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Avant Diagnostics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Avant Diagnostics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Avant Diagnostics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avant Diagnostics Cyclically Adjusted PS Ratio Chart

Avant Diagnostics Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Sep14 Sep15 Sep16 Sep17 Sep18
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Avant Diagnostics Quarterly Data
Jan14 Apr14 Jul14 Oct14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avant Diagnostics's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Avant Diagnostics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avant Diagnostics's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Avant Diagnostics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Avant Diagnostics's Cyclically Adjusted PS Ratio falls into.



Avant Diagnostics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Avant Diagnostics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2018 is calculated as:

For example, Avant Diagnostics's adjusted Revenue per Share data for the three months ended in Dec. 2018 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2018 (Change)*Current CPI (Dec. 2018)
=0/105.9979*105.9979
=0.000

Current CPI (Dec. 2018) = 105.9979.

Avant Diagnostics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200901 0.000 89.084 0.000
200904 0.000 89.968 0.000
200907 0.000 90.859 0.000
200910 0.000 91.207 0.000
201001 0.000 91.423 0.000
201004 0.000 91.980 0.000
201007 0.000 91.981 0.000
201010 0.000 92.277 0.000
201101 0.000 92.914 0.000
201104 0.000 94.890 0.000
201107 0.000 95.319 0.000
201110 0.000 95.529 0.000
201201 0.000 95.632 0.000
201204 0.000 97.075 0.000
201207 0.000 96.661 0.000
201210 0.000 97.595 0.000
201301 0.000 97.158 0.000
201304 0.000 98.107 0.000
201307 0.000 98.557 0.000
201310 0.000 98.536 0.000
201401 0.000 98.692 0.000
201404 0.000 100.023 0.000
201407 0.000 100.520 0.000
201410 0.000 100.176 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.001 101.688 0.001
201609 0.000 101.861 0.000
201612 0.001 101.863 0.001
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Avant Diagnostics  (GREY:AVDX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Avant Diagnostics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Avant Diagnostics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avant Diagnostics (Avant Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
1050 30th Street NW, Suite 107, Washington, DC, USA, 20007
Avant Diagnostics Inc is a medical diagnostic technology company. Business activity of the group is functioned through United States. It focuses on the commercialization of a series of proprietary microarray-based diagnostic tests that provide early detection of cancers, neurodegenerative diseases, and other chronic and severe disease states. The company's premier product is OvaDx, a non-invasive proteomics diagnostic screening test for the early detection of ovarian cancer.